Cargando…

Patient Preference for Biologic Treatments of Psoriasis in the Chinese Setting

OBJECTIVE: Assessments of patients’ preferences can support in clinical decision-making regarding biologic therapies for psoriasis. Our objective was to investigate patient preference for biologic treatments in patients with psoriasis in China. METHODS: From October 2020 to January 2021, psoriasis p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lang, Yitian, Wu, Bin, Sun, Zhilin, Ye, Erjia, Dou, Guanshen, Guan, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038155/ https://www.ncbi.nlm.nih.gov/pubmed/35479654 http://dx.doi.org/10.2147/PPA.S357795

Ejemplares similares

Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry
por: Yu, Chen, et al.
Publicado: (2022)

Patient preference for biologic treatments of psoriasis in Japan
por: Tada, Yayoi, et al.
Publicado: (2019)

Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment
por: Kromer, Christian, et al.
Publicado: (2015)

Safety and Efficacy of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: A Prospective, Multicenter, Observational Study
por: Ying, Li, et al.
Publicado: (2023)

Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients
por: Schaarschmidt, Marthe-Lisa, et al.
Publicado: (2015)

Biologics for psoriasis patients under 18 years of age: Real-world evidence from the Chinese psoriasis real world evidence research group
por: Zheng, Yu-Xin, et al.
Publicado: (2022)

Dermatologist and Patient Preferences in Choosing Treatments for Moderate to Severe Psoriasis
por: Alcusky, Matthew, et al.
Publicado: (2017)

Patient Preferences for Topical Psoriasis Treatments are Diverse and Difficult to Predict
por: Iversen, Lars, et al.
Publicado: (2016)

Preference for Telemedicine Versus In-Person Visit Among Patients with Psoriasis Receiving Biological Drugs
por: Gisondi, Paolo, et al.
Publicado: (2021)

Effectiveness and safety of secukinumab in Chinese patients with plaque psoriasis in a clinical practice setting: a pilot study
por: Zhu, Si-Man, et al.
Publicado: (2020)

Predicting treatment success with biologics in psoriasis
por: van den Reek, J.M.P.A.
Publicado: (2019)

Biologic Treatments of Psoriasis: An Update for the Clinician
por: Brownstone, Nicholas D, et al.
Publicado: (2021)

Neurological Complications of Biological Treatment of Psoriasis
por: Ożóg, Mateusz Kamil, et al.
Publicado: (2022)

The Cost Effectiveness of Biologic Therapy for the Treatment of Chronic Plaque Psoriasis in Real Practice Settings in Italy
por: Spandonaro, Federico, et al.
Publicado: (2014)

Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis
por: Lynch, Maeve, et al.
Publicado: (2017)

Rapid response of spesolimab in biologics – failure patient with generalized pustular psoriasis flare
por: Jiang, Meng, et al.
Publicado: (2023)

Advancements in the Treatment of Psoriasis: Role of Biologic Agents
por: Rich, Sheldon J., et al.
Publicado: (2004)

Reliability and validity of the Chinese version of the Psoriasis Disability Index (PDI) in Chinese patients with psoriasis
por: He, Zehui, et al.
Publicado: (2012)

BIOLOGICAL THERAPY OF PSORIASIS
por: Sivamani, Raja K, et al.
Publicado: (2010)

Biologics in the management of psoriasis
por: Bahner, Jennifer D, et al.
Publicado: (2009)

Biologics and Biosimilars in Psoriasis
por: Ahmed, Sk Shahriar, et al.
Publicado: (2023)

The Patient’s Guide to Psoriasis Treatment. Part 3: Biologic Injectables
por: Abrouk, Michael, et al.
Publicado: (2016)

Effects of Chinese Formula Jueyin Granules on Psoriasis in an Animal Model
por: Ma, Tian, et al.
Publicado: (2014)

Biological markers in the etiology of psoriasis: Targeted treatment options
por: de Felice, Catia, et al.
Publicado: (2007)

Emerging treatments in the management of psoriasis: biological targeting with ustekinumab
por: Papoutsaki, Marina, et al.
Publicado: (2009)

Quo vadis, biological treatment for psoriasis and psoriatic arthritis?
por: Olszewska, Barbara, et al.
Publicado: (2018)

Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis
por: Cline, Abigail, et al.
Publicado: (2019)

Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature
por: Belinchón, I, et al.
Publicado: (2016)

Relative Importance of Mode of Administration in Treatment Preferences among Plaque Psoriasis Patients in the United States
por: Feldman, Steven R., et al.
Publicado: (2016)

A nomogram diagnostic cardiovascular disease in patients with erythrodermic psoriasis in Chinese
por: Zou, Yue-Min, et al.
Publicado: (2023)

Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting
por: Strober, Bruce, et al.
Publicado: (2022)

A review of Chinese medicine for the treatment of psoriasis: principles, methods and analysis
por: Su, Yang, et al.
Publicado: (2021)

Does the leading pharmaceutical reform in China really solve the issue of overly expensive healthcare services? Evidence from an empirical study
por: He, Yunzhen, et al.
Publicado: (2018)

Anatomy of provincial level inequality in maternal mortality in China during 2004–2016: a new decomposition analysis
por: Zhang, Xinyu, et al.
Publicado: (2020)

Demographics and the perception of psoriasis therapy adverse effects and treatment preference: A cross-sectional survey of a convenience sample of people with psoriasis
por: Bray, Jeremy K., et al.
Publicado: (2020)

Biologics use in Indian psoriasis patients
por: Rajagopalan, Murlidhar, et al.
Publicado: (2016)

Real-world investigation of the efficacy and safety of secukinumab for psoriasis treatment in a Chinese population
por: Zeng, Jing-Xin, et al.
Publicado: (2021)

Preferences for Treatment Setting by Substance Users in India
por: Dhawan, Anju, et al.
Publicado: (2016)

The cost of biologics for psoriasis is increasing
por: Cheng, Judy, et al.
Publicado: (2014)

COVID, Biologics, and Psoriasis Therapy
por: Elston, Dirk M.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_44p6uhpecrlabp2eut7rrfrlml